Patricia Brundage, PhD

Lead Interdisciplinary Scientist / Pharmacologist
US FDA

Presentation(s):

• Nonclinical Program Considerations for Peptide Safety Assessment (S02)

  Monday, November 18, 2024
  9:00 AM - 12:00 PM CT

• Nonclinical Considerations for Development of Peptides: A CDER Perspective (S02-2)

  Monday, November 18, 2024
  9:25 AM - 9:50 AM CT